Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With positive top-line pivotal trial results for its lead antibody drug conjugate SGN-35 for Hodgkin's lymphoma in hand, Seattle Genetics aims to file a BLA for the compound in the first half of 2011 and is hoping as well for priority review

You may also be interested in...



On The Horizon: Planned Filings For Novel Drugs In 2011

On top of the full slate of pending applications, the pool of potential novel product approvals in 2011 continues to grow as more submissions come in.

On The Horizon: Planned Filings For Novel Drugs In 2011

On top of the full slate of pending applications, the pool of potential novel product approvals in 2011 continues to grow as more submissions come in.

On The Horizon: Planned Filings For Novel Drugs In 2011

On top of the full slate of pending applications, the pool of potential novel product approvals in 2011 continues to grow as more submissions come in.

Related Content

Topics

UsernamePublicRestriction

Register

PS004568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel